| 000 | 01801 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516001917.0 | ||
| 264 | 0 | _c20101207 | |
| 008 | 201012s 0 0 eng d | ||
| 022 | _a1533-7294 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCampbell, R Keith | |
| 245 | 0 | 0 |
_aDistinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. _h[electronic resource] |
| 260 |
_bThe Journal of family practice _cSep 2010 |
||
| 300 |
_aS10-9 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Journal Article | ||
| 650 | 0 | 4 |
_aAdamantane _xanalogs & derivatives |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aBlood Glucose |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 |
_aDipeptides _xtherapeutic use |
| 650 | 0 | 4 |
_aDipeptidyl-Peptidase IV Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aExenatide |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlucagon _xmetabolism |
| 650 | 0 | 4 |
_aGlucagon-Like Peptide 1 _xagonists |
| 650 | 0 | 4 | _aGlucagon-Like Peptide-1 Receptor |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xmetabolism |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aIncretins _xpharmacology |
| 650 | 0 | 4 |
_aInsulin _xmetabolism |
| 650 | 0 | 4 | _aInsulin Resistance |
| 650 | 0 | 4 | _aLiraglutide |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetformin _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptides _xtherapeutic use |
| 650 | 0 | 4 |
_aPyrazines _xtherapeutic use |
| 650 | 0 | 4 | _aReceptors, Glucagon |
| 650 | 0 | 4 | _aSitagliptin Phosphate |
| 650 | 0 | 4 |
_aTriazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aVenoms _xtherapeutic use |
| 700 | 1 | _aCobble, Michael E | |
| 700 | 1 | _aReid, Timothy S | |
| 700 | 1 | _aShomali, Mansur E | |
| 773 | 0 |
_tThe Journal of family practice _gvol. 59 _gno. 9 Suppl 1 _gp. S10-9 |
|
| 999 |
_c20156660 _d20156660 |
||